GlassScriptPhysician profile
Jaime L Haidet
NPI 1497967442
$412.49
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $75.45 | 2019-2020 | |
| Insulet Corporation | $60.71 | 2019 | |
| Novo Nordisk INC | $49.33 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $45.53 | 2019 | |
| Dexcom, INC. | $39.24 | 2019 | |
| Pfizer INC. | $26.80 | 2019 | |
| Endo Pharmaceuticals INC. | $14.91 | 2019 | |
| Medtronic Minimed, INC. | $14.12 | 2019 | |
| Becton, Dickinson and Company | $13.74 | 2019 | |
| Lilly USA, LLC | $13.58 | 2020 | |
| Sun Pharmaceutical Industries INC. | $12.70 | 2020 | |
| Lifescan, INC. | $12.68 | 2020 | |
| Abbott Laboratories | $11.55 | 2019 | |
| Ibsa Pharma INC. | $11.09 | 2019 | |
| Tandem Diabetes Care, INC. | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Haidet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.